Key facts
- This page summarizes Steven H. Stein's Form 4 filing for Theseus Pharmaceuticals, Inc..
- 2 reported transactions and 2 derivative rows are listed below.
- Accepted by SEC: 13 Jun 2023, 17:30.
Steven H. Stein - 13 Jun 2023 Form 4 Insider Report for Theseus Pharmaceuticals, Inc.
- Reporting relationship
- Director
- Issuer ticker
- N/A
- Reported as of
- 13 Jun 2023
- Net transaction value
- $0
- SEC form
- 4
- Accepted by SEC
- 13 Jun 2023, 17:30:09 UTC
- Prior SEC filing
- 24 Jan 2023
- Next SEC filing
- 06 Jul 2023
- Source filing
- View source filing
- Reporting owner signature
- /s/ Bradford Dahms - Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Steven H. Stein filed Form 4 for Theseus Pharmaceuticals, Inc. on 13 Jun 2023.
Change
- Previous filing in this sequence was filed on 24 Jan 2023.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
THRX
transaction
Derivative
Stock Option (right to buy)
Award
- Transaction value
- $0
- Shares
- +19,500
- Change %
- Price
- $0.000000
- Shares after
- 19,500
- Date
- 13 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 19,500
- Exercise price
- $9.61
- Footnotes
- F1
THRX
transaction
Derivative
Restricted Stock Unit
Award
- Transaction value
- $0
- Shares
- +3,250
- Change %
- Price
- $0.000000
- Shares after
- 3,250
- Date
- 13 Jun 2023
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 3,250
- Exercise price
- Footnotes
- F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The options are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date.
Footnote F2
Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of Common Stock, par value $0.001 per share, when vested.
Footnote F3
The RSUs are subject to a service-based vesting requirement, which shall be satisfied on the earlier of (i) June 9, 2024 or (ii) the day prior to the date of the issuer's next annual meeting of stockholders, subject to the Reporting Person's continuous service with the issuer on such vesting date. The RSUs have no expiration date.